Gilead acquires XinThera to strengthen pipeline in oncology

Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors

Galmed Pharmaceuticals forms partnership with OnKai

Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications

Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform

Nous-209 has been developed using the Nouscom's viral vector platform

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science

Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India

CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology

LTS acquires Sorrel wearable injection device business

The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.

Vaniam appoints Paula Franson to lead Clinical Strategy & Solutions

Franson will help biopharma clients design a phased approach to inform and execute clinical development plans

NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate

Study efficacy measures will include the expression of dystrophin protein and motor function.

Bridgewest Group launches new sterile injectable CDMO NovaCina